LMI Selected to Support the Food and Drug Administration Business Operations, Optimization, and Modernization BPA

Tysons, Va.—LMI recently announced it will support the Food and Drug Administration (FDA) through the Business Operations, Optimization, and Modernization (BOOM) Blanket Purchase Agreement (BPA), in optimizing and modernizing its business operations to align with strategic priorities and increase the effectiveness of FDA organizations. This 5-year BPA has an estimated ceiling value of $149 million.

LMI will deliver a broad set of service areas to deliver tactical and strategic support of FDA’s near and long-term activities. These task areas include strategic planning, new business model development, organizational change management, policy effectiveness studies, resource and risk modeling, program and project management support, performance management services, coaching and mentoring, and project transition services. The goal of this support is to offer measurable accountability and continuous improvement of the organizational structures, policies, and processes that govern resource management.

“With over 15 years of history with the FDA, LMI is privileged to continue strengthening this strategic partnership through the BOOM BPA,” said Zaki Saleh, senior vice president, health & civilian market. “We look forward to improving the utilization of resources, process, and systems for the FDA, ensuring the seamless integration of projects and missions, and ultimately delivering protection and promotion of public health.”

LMI will provide its full range of digital transformation capabilities to ensure proper and effective alignment with the FDA’s strategic goals and objectives, while implementing Innovation at the Pace of Need^®. These capabilities include new and revised business models; structured and productive sharing of technical, functional, process knowledge and skills; increased effectiveness of FDA policies, validity of related methods, business processes, and systems; increased access to trained and equipped resources; and increased use of data-driven, risk- and evidence-based decision making for scoping opportunities and measuring results.